dc.contributor.author | Hadden, M. Kyle | |
dc.contributor.author | Blagg, Brian S. J. | |
dc.date.accessioned | 2017-04-13T15:37:29Z | |
dc.date.available | 2017-04-13T15:37:29Z | |
dc.date.issued | 2009-07-03 | |
dc.identifier.citation | Hadden, M. K., & Blagg, B. S. J. (2009). Synthesis and Evaluation of Radamide Analogues, A Chimera of Radicicol and Geldanamycin. The Journal of Organic Chemistry, 74(13), 4697–4704. http://doi.org/10.1021/jo900278g | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23680 | |
dc.description.abstract | Previously, we reported the Hsp90 inhibitory activity of radamide, an open chain amide chimera of geldanamycin and radicicol. Attempts to further expand upon structure–activity relationships for this class of Hsp90 inhibitors led to the preparation of a series of radamide analogues focused on differing tether lengths and quinone mimics. In addition, the cup-shaped conformation adopted by the two natural products when bound to the Hsp90 N-terminal ATP binding pocket suggests that conformationally biased compounds may demonstrate improved binding and inhibition. The preparation and evaluation of radamide analogues with cis/trans α,β-unsaturated amides yielded compounds that exhibit improved antiproliferative activity. In addition, several analogues demonstrated the ability to induce degradation of Hsp90-dependent oncogenic signaling proteins in vitro, a hallmark of Hsp90 N-terminal inhibition. | en_US |
dc.publisher | American Chemical Society | en_US |
dc.rights | This document is the Accepted Manuscript version of a Published Work that appeared in final form in the Journal of Organic Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://dx.doi.org/10.1021/jo900278g. | en_US |
dc.title | Synthesis and Evaluation of Radamide Analogues, A Chimera of Radicicol and Geldanamycin | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Hadden, M. Kyle | |
kusw.kuauthor | Blagg, Brian S. J. | |
kusw.kudepartment | Medicinal Chemistry | en_US |
kusw.oanotes | Per SHERPA/RoMEO 4/13/2017: Author's Pre-print: grey tick subject to Restrictions below, author can archive pre-print (ie pre-refereeing)
Restrictions: Must obtain written permission from Editor
Must not violate ACS ethical GuidelinesAuthor's Post-print: grey tick subject to Restrictions below, author can archive post-print (ie final draft post-refereeing)
Restrictions: If mandated by funding agency or employer/ institution
If mandated to deposit before 12 months, must obtain waiver from Institution/Funding agency or use AuthorChoice
12 months embargoPublisher's Version/PDF: cross author cannot archive publisher's version/PDF
General Conditions: On author's personal website, pre-print servers, institutional website, institutional repositories or subject repositories
Non-Commercial
Must be accompanied by set statement (see policy)
Must link to publisher version
Publisher's version/PDF cannot be used | en_US |
dc.identifier.doi | 10.1021/jo900278g | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | |